28Feb 2017

EVALUATION OF IMMUNOGENICITY OF DNA VACCINE CODING OUTER MEMBRANE PROTEIN 31 (OMP31) OF BRUCELLA MELITENSIS IN MICE.

  • Infectious Diseases Unit, Animal Health Department, Desert Research Center, Cairo, Egypt.
  • Veterinary Serum and Vaccine Research Institute,Sera and Antigens Department, Abbasia, Cairo, Egypt.
  • Parasitology Unit, Animal Health Department, Desert Research Center, Cairo, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Brucellosis is causing serious medical and economic crisis, therefore there are many efforts to prevent infection through vaccination. Attenuated Br. Melitensis Rev 1 vaccine is considered the best vaccine available for now, but it has serious drawbacks. In the present work, Omp31 of B. melitensis vaccine (vectored vaccine) was evaluated in mice, in comparison with Br. Melitensis Rev 1 vaccine. The immune response showed similar and different trends. After vaccination, the vectored vaccine group showed nearly the similar trend in the TNF-?, IL-1? and IL-12 (p40) levels with lower levels of IL-10, an anti-inflammatory cytokine, than B. Melitensis Rev 1 group. Moreover, vectored vaccine group showed lower weight, spleen and protective efficacy as those observed with B. Melitensis Rev 1vaccine. In addition, vectored vaccineism less biohazardous, well-defined and non-infectious. The obtained results document effectivity of the vectored vaccine and can be considered as a promising candidate and could be included in the development of a multi-subunit vaccine in controlling of brucellosis.

  1. Jinkyung K., and A. S. Gary. 2003. Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans. Clin. Microbe. Rev. 65-78.
  2. Moriyon I, M.J. Grillo, D. Monreal,D. Gonzalez, C. Marin,I. Lopez-Gonii, . R.C. Mainar-Jaime, E. Moreno, and J.M. Blasco. 2004. Rough vaccines in animal brucellosis : Structural and genetic basis and present status. Vet. Res. 35 :1 38.
  3. Fernandez-Prada, C. M., M. Nikolich, R. Vemulapalli, N. Sriranganathan, S. M. Boyle, G. G. Schurig, T. L. Hadfield, and D. L. Hoover. 2001. Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. Infect. Immun. 69:4407 4416.
  4. Schurig G.G., N. Sriranganathan and M.J Corbel. Brucellosis vaccines: past, present and future. Vet Microbiol 2002;90:479-96.
  5. D. Perkins, S. J. Smither, and H. S. Atkins, “Towards a Brucella vaccine for humans,” FEMSMicrobiology Reviews, vol. 34, no. 3, pp. 379–394, 2010.
  6. A. Pasquevich, A. E. Iba˜nez, L. M. Coria et al., “An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice,” PLoS ONE, vol. 6, no. 1, article e16203, 2011.
  7. Ruecker and C. A.Guzm´an, “Vaccines: from empirical development to rational desing,” PLOS Pathogens, vol. 8, no. 11, Article ID e1003001, 2012.
  8. K. Gupta, G. Radhakrishnan, J.Harms, and G. Splitter, “Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis,” Vaccine, vol. 30, no. 27, pp. 4017–4022, 2012.
  9. Estein, S. M., J. Cassataro, N. Vizcaino, M. S. Zygmunt, A. Cloeckaert, and R. A. Bowden. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella Ovis infection in BALB/c mice. Microbes Infect. 5:85-93.
  10. Al-Mariri, A., A. Tibor, P. Mertens, X. De Bolle, P. Michel, J. Godefroid, K. Walravens, and J. J. Letesson. 2001. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun. 69:4816-4822.
  11. Kamel, M. Y, Noha A. H and Amani A. H. 2014. Different Dna Extraction Techniques from Brucella melitensis 16M. Int J Microbiol Res 5 (1): 69-75.
  12. VizcaõÂno N, Verger J-M, Grayon M, Zygmunt MS, Cloeckaert A. 1997. DNA polymorphism at the omp-31 locus of Brucella spp.; evidence for a large deletion in Brucella abortus and other species-speci®c markers. Microbiology;143:2913±21.
  13. VizcaõÂno N, Cloeckaert A, Zygmunt MS, Dubray G. 1996. Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein. Infect Immun;64:3744±51
  14. Cassataro, J., K. Pasquevich, L. Bruno, J. C. Wallach, C. A. Fossati, and P. C. Baldi. 2004. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough brucellae. Clin. Diagn.Lab Immunol. 11:111–114.
  15. Cloeckaert, A., M. S. Zygmunt, P. de Wergifosse, G. Dubray, and J. N. Limet.1992. Demonstration of peptidoglycan-associated Brucella outer-membrane proteins by use of monoclonal antibodies. J. Gen. Microbiol. 138:1543–1550.
  16. Grilló MJ, Blasco JM, Gorvel JP, Moriyón I, Moreno E: (2012): What have we learned from brucellosis in the mouse model? Vet Res, 43:29.
  17. Guilloteau, L. A., K. Laroucau, N. Vizcaino, I. Jacques, and G. Dubray. 1999. Immunogenicity of recombinant Escherichia coli expressing the omp31 gene of Brucella melitensis in BALB/c mice. Vaccine17:353-361.
  18. Fernández-Lago L, Monte M, Chordi A: Endogenous gamma interferon and interleukin-10 in Brucella abortus 2308 infection in mice. FEMS Immunol Med Microbiol 1996, 15:109–114.
  19. Fernández-Lago L, Rodríguez-Tarazona E, Vizcaíno N: Differential secretion of interleukin-12 (IL-12) subunits and heterodimeric IL-12p70 protein by CD-1 mice and murine macrophages in response to intracellular infection by Brucella abortus. J MED Microbiol 1999, 48:1065–1073.
  20. Fernández-Lago L, Orduña A, Vizcaíno N: Reduced interleukin-18 secretion in Brucella abortus 2308-infected murine peritoneal macrophages and in spleen cells obtained from B. abortus 2308-infected mice. J MED Microbiol 2005, 54:527–531.
  21. Blasco JM, 1997. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet MED 31:275–283.
  22. Godfroid J, Scholz HC, Barbier T, Nicolas C, Wattiau P, Fretin D, Whatmore AM, Cloeckaert A, Blasco JM, Moriyón I, Saegerman C, Muma JB, Al Dahouk S, Neubauer H, Letesson JJ, 2011: Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev Vet MED, 102:118–131
  23. Kaufmann, A. F., M. I. Meltzer, and G. P. Schmid. 1997. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg. Infect. Dis. 3:83–94.
  24. Kroger, Andrew T.; Ciro V. Sumaya; Larry K. Pickering; William L. Atkinson (2011). "General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)". Morbidity and Mortality Weekly Report (MMWR). Centers for Disease Control and Prevention. Retrieved 2011-03-11.
  25. Hasanjani-Roushan MR, Kazemi S, Fallah-Rostami F, Ebrahimpour S. 2014. Brucellosis vaccines: an overview. Crescent J MED Biol Sci;1(4):118-124.
  26. TabatabaõÈ LB, Pugh GW, Jr. 1994. Modulation of immune responses in BALB/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine,12:919-24.
  27. Ertl HCJ, Xiang Z. 1996. Novel vaccine approaches. J Immunol; 156:3579-82.
  28. Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH, 2005: A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun, 73:6537–6546.
  29. Leclercq S, Harms JS, Olivereia SC. 2003. Enhanced capacity of DNA vaccines against an intracellular bacterial pathogen by genetic adjuvants. Curr Pharm Biotechnol, 4: 99-107.
  30. Ko, J., and G. A. Splitter. 2003. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin. Microbiol. Rev. 16:65–78.
  31. Jiménez de Bagüés MP, Elzer PH, Blasco JM, Marín CM, Gamazo C, Winter
  32. 1994. Protective immunity to Brucella Ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines. Infect Immun, 62:632–638.
  33. Murphy EA, Sathiyaseelan J, Parent MA, Zou B, Baldwin CL. 2001. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology, 103:511–518.
  34. Ben-Sasson SZ, Caucheteux S, Crank M, Hu-Li J, Paul WE. 2011. IL-1 acts on T cells to enhance the magnitude of in vivo immune responses. Cytokine, 56:122–125.
  35. Rutz S, Ouyang W. 2011. Regulation of interleukin-10 and interleukin-22 expression in T helper cells. Curr Opin Immunol, 23:605–612.
  36. Corsetti PP, de Almeida LA, Carvalho NB, Azevedo V, Silva TM, Teixeira HC, Faria AC, Oliveira SC. 2013. Lack of endogenous IL-10 enhances production of proinflammatory cytokines and leads to Brucella abortus clearance in mice. PLoS One, 8:e74729.
  37. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. 2009. The Brucella abortus S19 ?vjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun, 77:877–884.
  38. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. 2008. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun, 76:2448–2455.
  39. Wright PF, Nielsen KH. 1990. Current and future serological methods. In Advances in brucellosis research. Edited by Adams LG. College Station. USA:Texas A&M University Press, 1990.
  40. Zygmunt MS, Debbarh HS, Cloeckaert A, Dubray G. 1994. Antibody response to Brucella melitensis outer membrane antigens in naturally infected and Rev1 vaccinated sheep. Vet Microbiol, 39:33–46.
  41. Erridge C, Bennett-Guerrero E, Poxton IR. 2002. Structure and function of lipopolysaccharides. Microbes and Infection. 4:837–851. doi: 10.1016/S1286-4579(02)01604-0.
  42. Bowden RA, Cloeckaert A, Zygmunt MS, Bernard S, Dubray G. 1995. Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry. Infect Immun. 63:3945-52.
  43. Blasco JM. 1997. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet MED 31:275–283.
  44. Grilló MJ, Bosseray N, Blasco JM. 2000. In vitro markers and biological activity in mice of seed lot, strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologicals, 28:119–127.

[Yasser M. Kamel, Noha A. Helmy, Amani A. Hafez and Safaa M. Barghash. (2017); EVALUATION OF IMMUNOGENICITY OF DNA VACCINE CODING OUTER MEMBRANE PROTEIN 31 (OMP31) OF BRUCELLA MELITENSIS IN MICE. Int. J. of Adv. Res. 5 (Feb). 2277-2285] (ISSN 2320-5407). www.journalijar.com

Amani A. Hafez
Infectious Diseases Unit, Animal Health Department, Desert Research Center, Cairo, Egypt.

DOI:

Article DOI: 10.21474/IJAR01/3405      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3405

Download Full Paper

Download PDF No. of Downloads: 17 | No. of Views: 109